# US 2020/0390856 A1 · Methods of treating autoimmune disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390856 A1
- Document ID: US20200390856A1
- Status: Published application
- Kind: A1
- Application number: 16/767,392
- Filed: 2018-11-28
- Published: 2020-12-17
- Earliest claimed: 2017-11-29
- Assignees: UTI Limited Partnership
- Applicants: UTI Limited Partnership
- Inventors: Pedro SANTAMARIA
- Web page: https://patentgrep.com/patent/US20200390856A1

## CPC

- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/143: {with inorganic compounds}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 33/26: Iron; Compounds thereof
- A61K 38/1719: {Muscle proteins, e.g. myosin or actin}
- A61K 38/415: {Cytochromes}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/605: {MHC molecules or ligands thereof}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein are compositions and methods useful for treating autoimmune diseases and inflammatory disorders. The compositions and methods utilize ubiquitous, non-tissue specific antigens associated with major histocompatibility complexes (MHCs) and coupled to a nanoparticle core to induce regulatory T cells and regulatory B cells.

## Claims

### Claim 1

A composition for use in treating an autoimmune or inflammatory disease, the composition comprising:
a) a plurality of antigen-major histocompatibility complexes (antigen-MHCs), each antigen-MHC of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC molecule, wherein the ubiquitous autoantigen is not a tissue specific antigen of the autoimmune or inflammatory disease; and
b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers;
wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the MHC molecule is an MHC class II molecule.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the nanoparticle core is a metal or metal oxide.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the metal is iron.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the metal oxide is iron oxide.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the diameter is between about 5 nanometers and about 50 nanometers.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the diameter is between about 5 nanometers and about 25 nanometers.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1 to 7, wherein the plurality of antigen-MHCs is coupled to the nanoparticle core at an antigen-MHC to nanoparticle core ratio of at least 10:1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The composition of any one of claims 1 to 8, wherein the plurality of antigen-MHCs is coupled to the nanoparticle core at an antigen-MHC to nanoparticle core ratio of no more than about 150:1.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The composition of any one of claims 1 to 9, wherein the plurality of antigen-MHCs is coupled to the nanoparticle core at a density from about 0.4 to about 13 antigen-MHCs per 100 nm2 of nanoparticle core surface area.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of any one of claims 1 to 10, wherein the antigen-MHCs are covalently coupled to the nanoparticle core.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1 to 11, wherein the antigen-MHCs are coupled to the nanoparticle core by a polyethylene glycol (PEG) linker having a mass of less than about 5 kilodaltons.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The composition of any one of claims 1 to 12, wherein the nanoparticle core further comprises a biocompatible coating.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the ubiquitous autoantigen comprises a polypeptide derived from a protein that at steady-state exists in or on an intracellular compartment.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the intracellular compartment is cytosol, mitochondria, Golgi apparatus, endoplasmic reticulum, nucleus, or plasma membrane.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the intracellular compartment is a mitochondrion.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the ubiquitous autoantigen is pyruvate dehydrogenase complex-E2 component (PDC-E2).

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the ubiquitous autoantigen is Cytochrome P450 2D6 (CYP2D6).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the ubiquitous autoantigen is actin (ACTB).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the ubiquitous autoantigen is soluble liver antigen (SLA).

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the ubiquitous autoantigen is formimidoyltransferase-cyclodeaminase (FTCD).

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the ubiquitous autoantigen is myeloperoxidase (MPO).

### Claim 23 (depends on 17)

The composition of claim 17, wherein the ubiquitous autoantigen is selected from the group consisting of: PDC-E2353-367; PDC-E272-86; PDC-E2422-436; PDC-E2353-367; PDC-E280-94; PDC-E2535-549; PDC-E2629-648; PDC-E2122-135 PDC-E2249-263; and PDC-E2249-263.

### Claim 24 (depends on 17)

The composition of claim 17, wherein the ubiquitous autoantigen is selected from the group consisting of: PDC-E2422-436 and PDC-E280-94.

### Claim 25 (depends on 18)

The composition of claim 18, wherein the ubiquitous autoantigen is selected from the group consisting of: CYP2D6284-298; CYP2D6289-303; CYP2D6318-332; CYP2D6313-332; CYP2D6393-412; CYP2D6192-206; CYP2D65-19; CYP2D6293-307; CYP2D6219-233; CYP2D6237-251; CYP2D615-29; CYP2D6235-249; CYP2D6317-331; CYP2D6293-307; CYP2D6428-442; CYP2D6237-251; CYP2D614-28; CYP2D6199-213; CYP2D6450-464; CYP2D6301-315; CYP2D6452-466; CYP2D659-73; CYP2D6130-144; CYP2D6193-212; CYP2D6305-324; and CYP2D615-29.

### Claim 26 (depends on 19)

The composition of claim 19, wherein the ubiquitous autoantigen is selected from the group consisting of: ACTB202-216; ACTB170-184; ACTB245-259; ACTB245-259; ACTB187-201; ACTB172-186; ACTB131-145; ACTB131-145; ACTB171-185; ACTB129-143; ACTB164-178; ACTB25-39; and ACTB323-337.

### Claim 27 (depends on 19)

The composition of claim 19, wherein the ubiquitous autoantigen is selected from the group consisting of: ACTB146-160; ACTB18-32; and ACTB171-185.

### Claim 28 (depends on 20)

The composition of claim 20, wherein the ubiquitous autoantigen is selected from the group consisting of: SLA334-348; SLA196-210; SLA115-129; SLA373-386; SLA186-197; SLA342-256; SLA110-124; SLA299-313; SLA49-63; SLA260-274; SLA119-133; SLA86-100; SLA26-40; SLA331-345; SLA317-331; SLA171-185; SLA417-431; SLA359-373; SLA215-229; and SLA111-125.

### Claim 29 (depends on 21)

The composition of claim 21, wherein the ubiquitous autoantigen is selected from the group consisting of: FTCD439-453; FTCD381-395; FTCD297-311; FTCD525-539; FTCD218-232; FTCD495-509; FTCD262-276; FTCD300-314; FTCD259-273; FTCD490-504; FTCD389-403; and FTCD295-309.

### Claim 30 (depends on 21)

The composition of claim 21, wherein the ubiquitous autoantigen is selected from the group consisting of: FTCD271-285; FTCD498-512; and FTCD301-315.

### Claim 31 (depends on 22)

The composition of claim 22, wherein the ubiquitous autoantigen is selected from the group consisting of: MPO322-336; MPO714-728; MPO617-631; MPO504-518; MPO462-476; MPO617-631; MPO444-458; MPO689-703; MPO248-262; MPO511-525; MPO97-111; and MPO616-630.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The composition of any one of claims 1 to 31, further comprising a second plurality of antigen-major histocompatibility complexes (MHCs) coupled to the nanoparticle core, each antigen-MHC of the second plurality comprising an antigen.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the antigen of the second plurality of antigen-major histocompatibility complexes (MHCs) is a second ubiquitous autoantigen.

### Claim 34 (depends on 32)

The composition of claim 32, wherein the second ubiquitous autoantigen comprises a polypeptide derived from a protein that at steady-state exists in or on an intracellular compartment.

### Claim 35 (depends on 34)

The composition of claim 34, wherein the intracellular compartment is cytosol, mitochondria, Golgi apparatus, endoplasmic reticulum, nucleus, or plasma membrane.

### Claim 36 (depends on 34)

The composition of claim 34, wherein the intracellular compartment is a mitochondrion.

### Claim 37 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: PDC-E2353-367; PDC-E272-86; PDC-E2422-436; PDC-E2353-367; PDC-E280-94; PDC-E2535-549; PDC-E2629-648; PDC-E2122-135 PDC-E2249-263; and PDC-E2249-263.

### Claim 38 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: PDC-E2422-436 and PDC-E280-94.

### Claim 39 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: CYP2D6284-298; CYP2D6289-303; CYP2D6318-332; CYP2D6313-332; CYP2D6393-412, CYP2D6192-206; CYP2D65-19; CYP2D6293-307; CYP2D6219-233; CYP2D6237-251; CYP2D615-29; CYP2D6235-249; CYP2D6317-331; CYP2D6293-307; CYP2D6428-442; CYP2D6237-251; CYP2D614-28; CYP2D6199-213; CYP2D6450-464; CYP2D6301-315; CYP2D6452-466; CYP2D659-73; CYP2D6130-144; CYP2D6193-212; CYP2D6305-324; and CYP2D615-29.

### Claim 40 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: ACTB202-216; ACTB170-184; ACTB245-259; ACTB187-201; ACTB172-186; ACTB131-145; ACTB131-145; ACTB171-185; ACTB129-143; ACTB164-478; ACTB25-39; and ACTB323-337.

### Claim 41 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: ACTB146-160; ACTB18-32; and ACTB171-185.

### Claim 42 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: SLA334-348; SLA196-210; SLA115-129; SLA373-386; SLA186-197; SLA342-256; SLA110-124; SLA299-313; SLA49-63; SLA260-274; SLA119-133; SLA86-100; SLA26-40; SLA331-345; SLA317-331; SLA171-185; SLA417-431; SLA359-373; SLA215-229; and SLA111-125.

### Claim 43 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: FTCD439-453; FTCD381-395; FTCD297-311; FTCD525-539; FTCD218-232; FTCD495-509; FTCD262-276; FTCD300-314; FTCD259-273; FTCD490-504; FTCD389-403; and FTCD295-309.

### Claim 44 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: FTCD271-285; FTCD498-512; and FTCD301-315.

### Claim 45 (depends on 33)

The composition of claim 33, wherein the second ubiquitous autoantigen is selected from the group consisting of: MPO322-336; MPO714-728; MPO617-631; MPO504-518; MPO462-476; MPO617-631; MPO444-458; MPO689-703; MPO248-262; MPO511-525; MPO97-111; and MPO616-630.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The composition of any one of claims 1 to 45, further comprising a pharmaceutically acceptable stabilizer, excipient, diluent, or combination thereof.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The composition of any one of claims 1 to 46, formulated for intravenous administration.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The composition of any one of claims 1 to 47, wherein the autoimmune or inflammatory disease is selected from the group consisting of type I diabetes, multiple sclerosis, relapsing-remitting multiple sclerosis, pemphigus, pemphigus foliaceus, pemphigus vulgaris, neuromyelitis optica spectrum disorder, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, celiac disease, allergic asthma, systemic lupus erythematosus, atherosclerosis, chronic obstructive pulmonary disease, emphysema, psoriasis, uveitis, Sjogren's Syndrome, scleroderma, anti-phospholipid syndrome, ANCA-associated vasculitis, primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, and Stiff Man Syndrome.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the autoimmune or inflammatory disease is multiple sclerosis.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the ubiquitous autoantigen or the second ubiquitous autoantigen is not a polypeptide derived from myelin basic protein, myelin associated glycoprotein, myelin oligodendrocyte protein (MOG), proteolipid protein, oligodendrocyte myelin oligoprotein, myelin associated oligodendrocyte basic protein, oligodendrocyte specific protein, heat shock proteins, an oligodendrocyte specific protein, NOGO A, glycoprotein Po, peripheral myelin protein 22, or 2′3′-cyclic nucleotide 3′-phosphodiesterase.

### Claim 51 (depends on 48)

The composition of claim 48, wherein the autoimmune or inflammatory disease is type I diabetes.

### Claim 52 (depends on 51)

The composition or use of claim 51, wherein the ubiquitous autoantigen or the second ubiquitous autoantigen is not a polypeptide derived from pre-proinsulin, proinsulin, islet-specific glucose-6-phosphatase (IGRP), glutamate decarboxylase (GAD), islet cell autoantigen-2 (ICA2), or insulin.

### Claim 53

A method of treating an autoimmune or inflammatory disease in an individual comprising administering to an individual a composition comprising:
a) a plurality of antigen-major histocompatibility complexes (antigen-MHCs), each antigen-MHC of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC molecule, wherein the ubiquitous autoantigen is not a tissue specific antigen of the autoimmune or inflammatory disease; and
b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers;
wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core.

### Claim 54 (depends on 53)

The method of claim 53, wherein the MHC molecule is an MHC class II molecule.

### Claim 55 (depends on 53, 54)

The method of claim 53 or 54, wherein the nanoparticle core is a metal or metal oxide.

### Claim 56 (depends on 55)

The method of claim 55, wherein the metal is iron.

### Claim 57 (depends on 55)

The method of claim 55, wherein the metal oxide is iron oxide.

### Claim 58 (depends on 53, 54, 55, 56, 57)

The method of any one of claims 53 to 57, wherein the diameter is between about 5 nanometers and about 50 nanometers.

### Claim 59 (depends on 58)

The method of claim 58, wherein the diameter is between about 5 nanometers and about 25 nanometers.

### Claim 60 (depends on 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 53 to 59, wherein the antigen-MHCs are coupled to the nanoparticle core at an antigen-MHC to nanoparticle core ratio of at least 10:1.

### Claim 61 (depends on 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 53 to 60, wherein the antigen-MHCs are coupled to the nanoparticle core at an antigen-MHC to nanoparticle core ratio of no more than about 150:1.

### Claim 62 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 53 to 61, wherein the antigen-MHCs are coupled to the nanoparticle core at a density from about 0.4 to about 13 antigen-MHCs per 100 nm2 of nanoparticle core surface area.

### Claim 63 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 53 to 62, wherein the antigen-MHCs are covalently coupled to the nanoparticle core.

### Claim 64 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 53 to 63, wherein the antigen-MHCs are coupled to the nanoparticle core by a polyethylene glycol (PEG) linker having a mass of less than about 5 kilodaltons.

### Claim 65 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 53 to 64, wherein the nanoparticle core further comprises a biocompatible coating.

### Claim 66 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 53 to 65, wherein the ubiquitous autoantigen comprises a polypeptide derived from a protein that at steady-state exists in or on an intracellular compartment.

### Claim 67 (depends on 66)

The method of claim 66, wherein the intracellular compartment is cytosol, mitochondria, Golgi apparatus, endoplasmic reticulum, nucleus, or plasma membrane.

### Claim 68 (depends on 66)

The method of claim 66, wherein the intracellular compartment is a mitochondrion.

### Claim 69 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 53 to 68, wherein the ubiquitous autoantigen is pyruvate dehydrogenase complex-E2 component (PDC-E2).

### Claim 70 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 53 to 65, wherein the ubiquitous autoantigen is Cytochrome P450 2D6 (CYP2D6).

### Claim 71 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 53 to 65, wherein the ubiquitous autoantigen is actin (ACTB).

### Claim 72 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 53 to 65, wherein the ubiquitous autoantigen is soluble liver antigen (SLA).

### Claim 73 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 53 to 65, wherein the ubiquitous autoantigen is formimidoyltransferase-cyclodeaminase (FTCD).

### Claim 74 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 53 to 65, wherein the ubiquitous autoantigen is myeloperoxidase (MPO).

### Claim 75 (depends on 69)

The method of claim 69, wherein the ubiquitous autoantigen is selected from the group consisting of: PDC-E2353-367; PDC-E272-86; PDC-E2422-436; PDC-E2353-367; PDC-E280-94; PDC-E2535-549; PDC-E2629-648; PDC-E2122-135 PDC-E2249-263; and PDC-E2249-263.

### Claim 76 (depends on 69)

The method of claim 69, wherein the ubiquitous autoantigen is selected from the group consisting of: PDC-E2422-436 and PDC-E280-94.

### Claim 77 (depends on 70)

The method of claim 70, wherein the ubiquitous autoantigen is selected from the group consisting of: CYP2D6284-298; CYP2D6289-303; CYP2D6318-332; CYP2D6313-332; CYP2D6393-412; CYP2D6192-206; CYP2D65-19; CYP2D6293-307; CYP2D6219-233; CYP2D6237-251; CYP2D615-29; CYP2D6235-249; CYP2D6317-331; CYP2D6293-307, CYP2D6428-442; CYP2D6237-251; CYP2D614-28; CYP2D6199-213; CYP2D6450-464; CYP2D6301-315; CYP2D6452-466; CYP2D659-73; CYP2D6130-144; CYP2D6193-212; CYP2D6305-324; and CYP2D615-29.

### Claim 78 (depends on 71)

The method of claim 71, wherein the ubiquitous autoantigen is selected from the group consisting of: ACTB202-216; ACTB170-184; ACTB245-259; ACTB245-259; ACTB187-201; ACTB172-186; ACTB131-145; ACTB131-145; ACTB171-185; ACTB129-143; ACTB164-178; ACTB25-39; and ACTB323-337.

### Claim 79 (depends on 71)

The method of claim 71, wherein the ubiquitous autoantigen is selected from the group consisting of: ACTB146-160; ACTB18-32; and ACTB171-185.

### Claim 80 (depends on 72)

The composition of claim 72, wherein the ubiquitous autoantigen is selected from the group consisting of: SLA334-348; SLA196-210; SLA115-129; SLA373-386; SLA186-197; SLA342-256; SLA110-124; SLA299-313; SLA49-63; SLA260-274; SLA119-133; SLA86-100; SLA26-40; SLA331-345; SLA317-331; SLA171-185; SLA417-431; SLA359-373; SLA215-229; and SLA111-125.

### Claim 81 (depends on 73)

The method of claim 73, wherein the ubiquitous autoantigen is selected from the group consisting of: FTCD439-453; FTCD381-395; FTCD297-311; FTCD525-539; FTCD218-232; FTCD495-509; FTCD262-276; FTCD300-314; FTCD259-273; FTCD490-504; FTCD389-403; and FTCD295-309.

### Claim 82 (depends on 73)

The method of claim 73, wherein the ubiquitous autoantigen is selected from the group consisting of: FTCD271-285; FTCD498-512; and FTCD301-315.

### Claim 83 (depends on 74)

The method of claim 74, wherein the ubiquitous autoantigen is selected from the group consisting of: MPO322-336; MPO714-728; MPO617-631; MPO504-518; MPO462-476; MPO617-631; MPO444-458; MPO686-703; MPO248-262; MPO511-525; MPO97-111; and MPO616-630.

### Claim 84 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 53 to 83, wherein the composition further comprises a second plurality of antigen-major histocompatibility complexes (MHCs) coupled to the nanoparticle core, each antigen-MHC of the second plurality comprising an antigen.

### Claim 85 (depends on 84)

The method of claim 84, wherein the antigen of the second plurality of antigen-major histocompatibility (MHC) complexes is a second ubiquitous autoantigen.

### Claim 86 (depends on 85)

The method of claim 85, wherein the ubiquitous autoantigen comprises a polypeptide derived from a protein that at steady-state exists in or on an intracellular compartment.

### Claim 87 (depends on 86)

The method of claim 86, wherein the intracellular compartment is cytosol, mitochondria, Golgi apparatus, endoplasmic reticulum, nucleus, or plasma membrane.

### Claim 88 (depends on 86)

The method of claim 86, wherein the intracellular compartment is a mitochondrion.

### Claim 89 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: PDC-E2353-367; PDC-E272-86; PDC-E2422-436; PDC-E2353-367; PDC-E280-94; PDC-E2535-540; PDC-E2629-648; PDC-E2122-135 PDC-E2249-263; and PDC-E2249-263.

### Claim 90 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: PDC-E2422-436 and PDC-E280-94.

### Claim 91 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: CYP2D6284-298; CYP2D6289-303; CYP2D6318-332; CYP2D6313-332; CYP2D6393-412, CYP2D6192-206, CYP2D65-19; CYP2D6293-307, CYP2D6219-233, CYP2D6237-251; CYP2D615-29; CYP2D6235-249; CYP2D6317-331; CYP2D6293-307; CYP2D6428-442, CYP2D6237-251; CYP2D614-28; CYP2D6199-213; CYP2D6450-464; CYP2D6301-315; CYP2D6452-466, CYP2D659-73; CYP2D6130-144; CYP2D6193-212; CYP2D6305-324; and CYP2D615-29.

### Claim 92 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: ACTB202-216; ACTB170-184; ACTB245-259; ACTB187-201; ACTB172-186; ACTB131-145; ACTB131-145; ACTB171-185; ACTB129-143; ACTB164-178; ACTB25-39; and ACTB323-337.

### Claim 93 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: ACTB146-160; ACTB18-32; and ACTB171-185.

### Claim 94 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: SLA334-348; SLA196-210; SLA115-129; SLA373-386; SLA186-197; SLA342-256, SLA110-124; SLA299-313; SLA49-63; SLA260-274; SLA119-433; SLA86-100; SLA26-40; SLA331-345; SLA317-331; SLA171-485; SLA417-431; SLA359-373; SLA215-229; and SLA111-125.

### Claim 95 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: FTCD439-453; FTCD381-395; FTCD297-311; FTCD525-539; FTCD218-232; FTCD495-509, FTCD262-276; FTCD300-314; FTCD259-273; FTCD490-504; FTCD389-403; and FTCD295-309.

### Claim 96 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: FTCD271-285; FTCD498-512; and FTCD301-315.

### Claim 97 (depends on 85)

The method of claim 85, wherein the second ubiquitous autoantigen is selected from the group consisting of: MPO322-336; MPO714-728; MPO617-631; MPO504-518; MPO462-476; MPO617-631; MPO444-458; MPO689-703; MPO248-262; MPO511-525; MPO97-111; and MPO616-630.

### Claim 98 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 53 to 97, wherein the composition further comprises a pharmaceutically acceptable stabilizer, excipient, diluent, or any combination thereof.

### Claim 99 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method of any one of claims 53 to 98, wherein the composition is formulated for intravenous administration.

### Claim 100 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 53 to 99, wherein the ubiquitous autoantigen or the second ubiquitous autoantigen is not a polypeptide derived from myelin basic protein, myelin associated glycoprotein, myelin oligodendrocyte protein (MOG), proteolipid protein, oligodendrocyte myelin oligoprotein, myelin associated oligodendrocyte basic protein, oligodendrocyte specific protein, heat shock proteins, an oligodendrocyte specific protein, NOGO A, glycoprotein Po, peripheral myelin protein 22, or 2′3′-cyclic nucleotide 3′-phosphodiesterase.

### Claim 101 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 53 to 99, wherein the ubiquitous autoantigen or the second ubiquitous autoantigen is not a polypeptide derived from pre-proinsulin, proinsulin, islet-specific glucose-6-phosphatase (IGRP), glutamate decarboxylase (GAD), islet cell autoantigen-2 (ICA2), or insulin.

### Claim 102 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 53 to 101, wherein the autoimmune or inflammatory disease is selected from the group consisting of type I diabetes, multiple sclerosis, relapsing-remitting multiple sclerosis, pemphigus, pemphigus foliaceus, pemphigus vulgaris, neuromyelitis optica spectrum disorder, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, celiac disease, allergic asthma, systemic lupus erythematosus, atherosclerosis, chronic obstructive pulmonary disease, emphysema, psoriasis, uveitis, Sjogren's Syndrome, scleroderma, anti-phospholipid syndrome, ANCA-associated vasculitis, primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, and Stiff Man Syndrome.

### Claim 103 (depends on 102)

The method of claim 102, wherein the autoimmune or inflammatory disease is multiple sclerosis.

### Claim 104 (depends on 102)

The method of claim 102, wherein the autoimmune or inflammatory disease is type I diabetes.
